Evaluation of the HER2/<i>neu</i>‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trial

Abstract

GP2 is a clinically relevant HER2/neu-derived peptide with immunogenicity comparable to that of E75. Importantly, GP2-specific effectors recognize 2VGP2-expressing targets; therefore, a GP2 vaccine should be effective in patients carrying this polymorphism. GP2 may be most beneficial used in a multiepitope vaccine.